C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy

Trial Profile

C-Cure - Safety, Feasibility and Efficacy of Guided Bone Marrow-derived Mesenchymal Cardiopoietic Cells for the Treatment of Heart Failure Secondary to Ischemic Cardiomyopathy

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs C3BS CQR 1 (Primary)
  • Indications Cardiomyopathies; Chronic heart failure; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms C-CURE
  • Sponsors Cardio3 BioSciences
  • Most Recent Events

    • 11 Apr 2013 Phase II results have been published in the on-line edition of the Journal of the American College of Cardiology (JACC), according to a Cardio3 BioSciences media release.
    • 07 Nov 2011 New source identified and integrated (ical Trials Registry - India: CTRI2011-05-001742).
    • 31 Aug 2011 Results presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top